Navigation Links
China Pharma Holdings, Inc. Retains HC International, Inc. to Implement Investor Relations Program
Date:1/14/2008

NEW YORK and HAIKOU, China, Jan. 14 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (''China Pharma'') (OTC Bulletin Board: CPHI) which develops, manufactures, and markets generic and brand bio-pharmaceutical products in China, today announced that it has retained HC International, Inc. (HCI) to initiate a proactive and targeted investor relations campaign. Matthew Hayden and Alan Sheinwald of HCI, and their collective team, will be advising the Company in all facets of public financial communications.

HC International is a premier information resource to institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. HCI will leverage its recognized investment community relationships to help capitalize on China Pharma's key assets while helping management to articulate its accomplishments to date and its future growth opportunities. Additionally, the firm will help to extend China Pharma's market development, investor awareness and shareholder communications.

China Pharma, through its subsidiary, Hainan Helpson Bio-pharmaceutical Co., Ltd, is a specialty pharmaceutical company that develops, manufactures and markets generic and brand pharmaceutical products for both western and traditional Chinese medicines in China. The Company focuses on therapeutics for CNS, cardiovascular, cerebrovascular, wound recovery, and infectious diseases. Its products are sold in more than 20 provinces, sovereignties, and autonomous regions through 16 sales offices and approximately 680 proxy agents in China. China Pharma generated revenues of $24.0 million and net income of $8.8 million in the first nine months of 2007, up 75.6% and 72.0%, respectively, from the same period of 2006.

"This is an exciting time for China Pharma Holdings, Inc. as we continue to expand our business,'' said Ms. Zhilin Li, CEO of China Pharma Holdings, Inc. "After careful review, we selected HC International to ensure that our shareholders and members of the investment community are properly informed of our growth strategy and competitive advantages, including our focus on addressing high mortality diseases in China which includes targeting specific patient populations. The team at HC International is well respected and has a proven track record of representing many successful China based, US listed companies, including those operating in the Pharmaceutical Industry. We are confident they will help us to improve our overall communication capabilities, which includes delivering our story and subsequent milestones to a larger, targeted base of investors.''

"China Pharma is a very profitable pharmaceutical manufacturer in China that is well positioned to capitalize on its core strengths to address a large emerging market opportunity," said Matthew Hayden, President of HC International. "Given its strong management team, research and development expertise, and diverse product pipeline of potential new drugs, China Pharma presents an attractive opportunity for investors by possessing the necessary assets to build shareholder value over the long term.''

About China Pharma Holdings, Inc., Inc.

China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .

About HC International, Inc.

HC International is a focused and dedicated organization that acts as a premier informational resource for institutional investors, hedge funds, buy and sell-side analysts, small to large brokerage firms and accredited investors. HC International helps their clients' companies package their corporate information in a clear, concise and consistent manner while facilitating introductions to the right investors at the most opportune time. For further information, please contact HC International directly, or visit the Company's Web site at http://www.hcinternational.net .

For more information, please contact:

China Pharma Holdings, Inc.

Sophia Yu

Tel: +86-898-6681-1730

Email: hps@chinapharmaholdings.com

HC International, Inc.

Alan Sheinwald

Tel: +1-914-669-0222

Email: Alan.sheinwald@hcinternational.net


'/>"/>
SOURCE China Pharma Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. China Medical Technologies to Participate in the Morgan Stanleys 2007 China Medical Corporate Day
4. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
5. China Technology Announces New Chief Financial Officer
6. China Medical Technologies Reports First Quarter Financial Results
7. China Medical Technologies to Participate in Credit Suisses 2007 Asian Technology Conference
8. China Technology Announces Entry to the Solar Energy Sector
9. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
10. Kiwa Bio-Tech Named Recommended Brand by the China Green Food Association
11. China Kangtai Cactus Biotech, Inc. Announces Plans for New Product Launch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... The Blavatnik Family Foundation ... six Finalists of the 2017 Blavatnik Regional Awards for Young Scientists. Established ... administered by the New York Academy of Sciences to honor the excellence of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ... hosting a Webinar titled, “Pathology is going digital. Is your lab ready?” with ... adoption best practices and how Proscia improves lab economics and realizes an increase ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer and Activator ... osteosarcoma. SBT-100 is able to cross the cell membrane and bind intracellular STAT3 ...
Breaking Biology Technology:
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/18/2017)... 18, 2017  Socionext Inc., a global expert in SoC-based imaging ... server, the M820, which features the company,s hybrid codec technology. A ... Tera Probe, Inc., will be showcased during the upcoming Medtec Japan ... at the Las Vegas Convention Center April ... Click here for ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
Breaking Biology News(10 mins):